AKT1 and cancer: Taken together, these studies indicate that PI3K/AKT pathway plays a pivotal role in the limitation of PARPi utilization in cancer treatment, and the potential utility of using AKT inhibition might overcome PARPi resistance and broaden PARPi clinical application.